BioVie Inc

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

BioVie's pipeline indications represent a combined addressable market size of more than $100 billion with high unmet medical needs. Phase 2 trials have provided evidence to indicate that NE3107 may improve cognition and function in Alzheimer's disease and dementia and may enhance motor control in Parkinson's disease.

BioVie Inc: A Catalyst-Rich Year Ahead

The biotech announced positive news from a pair of phase 2 clinical trials.

Why Shares of BioVie Rose 15.3% in December

ORLANDO, FL / ACCESSWIRE / December 29, 2022 / RedChip Companies will air a new interview BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, on The RedChip Money Report® on Bloomberg TV, this Saturday, Dec. 31, at 7 p.m. Eastern Time (ET).

BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in BioVie Inc. (BIVI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does BioVie Inc. (BIVI) Have the Potential to Rally 52% as Wall Street Analysts Expect?

Over the past few months, BioVie has reported good data from a Phase 2 trial in Alzheimer's and a Phase 2 placebo-controlled Parkinson's disease trial. The Phase 3 trial in Alzheimer's is ongoing.

BioVie: 9 Reasons For Enthusiasm

NEW YORK, NY / ACCESSWIRE / December 13, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with BioVie. Toni had the pleasure of recently conducting the Interview with Cuong Do, President & CEO BioVie Inc. (NASDAQ:BIVI).

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Cuong Do, President & CEO BioVie Inc.

If you are looking for stocks that are well positioned to maintain their recent uptrend, BioVie Inc. (BIVI) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in BioVie Inc. (BIVI) Should Keep going

The more investors learned about BioVie's latest clinical results, the more they liked.

Why BioVie Stock Is Soaring Today

BioVie Inc (NASDAQ:BIVI) said it has made significant progress with its clinical programs, including its drug candidate NE3107 showing a clinically meaningful increase in motor control in patients with Parkinson's disease who were treated with the drug for 28 days. In a letter to shareholders, BioVie CEO Cuong Do said over the course of 2022, the company provided positive topline results from its Alzheimer's Disease (AD) and Parkinson's Disease (PD) trials.

BioVie updates investors on its Alzheimer's and Parkinson's clinical programs

The clinical-stage biotech released data on its prospective Alzheimer's therapy.

Why BioVie's Shares Tumbled Tuesday

BioVie's NE3107 has now shown improvement of cognition and function on different Alzheimer's rating scales, supported by biomarkers and neuroimaging data. The data just released from a Phase 2 placebo-controlled trial in Parkinson's disease with the same drug again shows strong efficacy, particularly in younger patients.

BioVie: Treating Alzheimer's, Parkinson's, And Potentially Reversing The Biological Clock

BioVie Inc (NASDAQ:BIVI) has announced positive results from two Phase 2 trials assessing NE3107's potential in Parkinson's Disease (PD) and Alzheimer's Disease (AD). The NM201 study (NCT05083260) is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson's disease (PD) participants treated with carbidopa/levodopa and NE3107.

BioVie announces positive results from two Phase 2 trials assessing NE3107's potential in Parkinson's Disease and Alzheimer's Disease

Initial Data shows NE3107 may Reduce Horvath DNA Methylation SkinBlood Clock by 3.3 years after 3 months of treatment Initial Data shows NE3107 may Reduce Horvath DNA Methylation SkinBlood Clock by 3.3 years after 3 months of treatment

BioVie Announces Additional Findings from Phase 2 Alzheimer's Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

NE3107-treated patients experienced greater motor control in Parkinson's trial

BioVie Announces Positive Results for NE3107 in Parkinson's and Alzheimer's Phase 2 Trials

Company is Opting to Increase Study Size to 400 due to Fast Enrollment Pace Company is Opting to Increase Study Size to 400 due to Fast Enrollment Pace

BioVie's Phase 3 Trial Assessing NE3107 in Alzheimer's Disease Has Fully Enrolled the Targeted 316 Patients

Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.

Are Medical Stocks Lagging BioVie (BIVI) This Year?

CARSON CITY, Nev., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that three abstracts highlighting results of its Phase 2, open-label study of NE3107 in patients with Alzheimer's Disease (AD) were accepted for presentation at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting, to be held November 29-December 2, 2022 in San Francisco, CA.

BioVie to Present Data from Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's Disease at CTAD Annual Meeting

The mean of analysts' price targets for BioVie Inc. (BIVI) points to an 84% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think BioVie Inc. (BIVI) Could Surge 84%: Read This Before Placing a Bet

Is BioVie (BIVI) Stock Outpacing Its Medical Peers This Year?

Acumen Pharmaceuticals

Athira Pharma

Anavex Life Sciences

Biogen

Eli Lilly

Prothena

Roche Holding AG

Cassava Sciences Inc

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.

Trading Ideas On The Upcoming CTAD 2022 Conference

CARSON CITY, Nev., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract characterizing the hospitalization burden of patients with cirrhosis and ascites and receiving treatment via paracentesis has been selected for presentation at The Liver Meeting 2022, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting 2022 will be held Washington, DC, from November 4-6, 2022.

BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022

Topline Data Expected December 2022 Topline Data Expected December 2022

BioVie's Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled

BioVie recently presented one of the best cognition improvements ever reported in an open label study in Alzheimer's disease. Further reporting and biomarkers confirmed those improvements, making BioVie a serious contender in the Alzheimer's space.

BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year

RENO, Nev., Sept. 29, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the participation of its management team in a panel discussion and one-on-one investor meetings at Cantor Fitzgerald's Neurology & Psychiatry Conference, to be held October 6-7, 2022, in San Francisco, CA.

BioVie to Participate in Cantor Fitzgerald's Neurology & Psychiatry Conference

In a fresh press release from this morning, BioVie (NASDAQ: BIVI ) disclosed top-line results from a Phase 2 clinical trial for its Alzheimer's disease treatment, NE3107. The results were largely positive, and today's traders are pushing BIVI stock higher as a result.

News for BioVie Inc Stock (BIVI)